Showing results (11-20 of 339) with videos related to
Sort By:
Pageof 34
Therapeutic Advances in Respiratory Disease|September 6, 2013
Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidenceKavitha Kotha, John P ClancyChest|February 16, 2013
Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosisSteven M Rowe, Ginger Reeves, Heather Hathorne, et al.American Journal of Respiratory and Critical Care Medicine|June 23, 2012
Personalized medicine in cystic fibrosis: dawning of a new eraJohn P Clancy, Manu JainExpert Opinion on Orphan Drugs|January 3, 2017
CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on IvacaftorElizabeth L Kramer, John P ClancyExpert Opinion on Therapeutic Targets|November 24, 2017
TGFβ as a therapeutic target in cystic fibrosisElizabeth L Kramer, John P ClancyAnnual Review of Genomics and Human Genetics|February 25, 2016
Cystic Fibrosis and Its Management Through Established and Emerging TherapiesDavid R Spielberg, John P ClancyAnnals of the American Thoracic Society|July 10, 2020
Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical TrialScott D Sagel, Umer Khan, Sonya L Heltshe, et al.Handbook of Clinical Neurology|February 16, 2023
Lessons from other fields of medicine, Part 2: Cystic fibrosisKadambari Vijaykumar, Steven M RoweAmerican Journal of Respiratory Cell and Molecular Biology|March 10, 2007
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutationsJohn P Clancy, Steven M Rowe, Zsuzsa Bebok, et al.BMC Gastroenterology|July 13, 2019
The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case reportJ Dixon Johns, Steven M RowePageof 34